Drug Profile


Alternative Names: BPX-501; BPX-501 and AP1903; BPX-501-AP1903; BPX-501-rimiducid; CaspaCIDe; CaspaCIDe™ DLI

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Immunodeficiency disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haematological malignancies; Immunodeficiency disorders; Infections
  • Phase I Haemoglobinopathies; Immunological disorders; Metabolic disorders

Most Recent Events

  • 13 Mar 2017 Bellicum announces intention to submit MAA to EMA for Haematological malignancies and Immunodeficiency disorders in 2018
  • 13 Mar 2017 Bellicum plans a phase II trial in Acute-myeloid-leukaemia
  • 13 Mar 2017 Bellicum plans a phase II comparator trial for Haematological malignancies (In adolescents, In children, In infants) in EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top